Arch Therapeutics Targets mid-2016 For Commercial Launch Of AC5 Hemostatic Agent
This article was originally published in Clinica
Executive Summary
Arch Therapeutics has begun enrolling a 46-patient randomized trial to support a CE mark for its AC5 topical hemostatic agent by sometime in the summer, Arch Therapeutics president and CEO Terence Norchi told Clinica.